| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
|
Science
|
2006
|
27.96
|
|
2
|
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
|
Ann Neurol
|
2009
|
14.42
|
|
3
|
Frontotemporal dementia: clinicopathological correlations.
|
Ann Neurol
|
2006
|
5.14
|
|
4
|
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.
|
Nat Rev Drug Discov
|
2007
|
4.03
|
|
5
|
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.
|
Neurology
|
2012
|
3.58
|
|
6
|
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases.
|
Acta Neuropathol
|
2007
|
3.55
|
|
7
|
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
|
Ann Neurol
|
2005
|
3.09
|
|
8
|
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.
|
J Neuropathol Exp Neurol
|
2008
|
2.96
|
|
9
|
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
|
Brain
|
2007
|
2.96
|
|
10
|
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
|
Arch Neurol
|
2011
|
2.81
|
|
11
|
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative.
|
Lancet Neurol
|
2007
|
2.72
|
|
12
|
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
|
Alzheimers Dement
|
2010
|
2.68
|
|
13
|
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.
|
Arch Neurol
|
2002
|
2.58
|
|
14
|
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
|
Am J Pathol
|
2008
|
2.41
|
|
15
|
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
|
Neurology
|
2012
|
2.26
|
|
16
|
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
|
Arch Neurol
|
2008
|
2.25
|
|
17
|
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.
|
Ann Neurol
|
2010
|
2.20
|
|
18
|
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.
|
Arch Neurol
|
2010
|
2.19
|
|
19
|
Diagnostic evaluation of elderly patients with mild memory problems.
|
Ann Intern Med
|
2003
|
2.15
|
|
20
|
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.
|
Acta Neuropathol
|
2010
|
2.12
|
|
21
|
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.
|
Alzheimers Dement
|
2008
|
1.90
|
|
22
|
Safety and acceptability of the research lumbar puncture.
|
Alzheimer Dis Assoc Disord
|
2005
|
1.82
|
|
23
|
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
|
Alzheimers Dement
|
2013
|
1.77
|
|
24
|
Monoaminergic orchestration of motor programs in a complex C. elegans behavior.
|
PLoS Biol
|
2013
|
1.69
|
|
25
|
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia.
|
Arch Neurol
|
2007
|
1.60
|
|
26
|
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
|
Biol Psychiatry
|
2010
|
1.59
|
|
27
|
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
|
Arch Neurol
|
2007
|
1.57
|
|
28
|
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions.
|
Arch Neurol
|
2007
|
1.57
|
|
29
|
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
|
Neurobiol Aging
|
2012
|
1.49
|
|
30
|
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations.
|
Arch Neurol
|
2007
|
1.45
|
|
31
|
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
|
Neurobiol Aging
|
2012
|
1.43
|
|
32
|
Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology.
|
Ann Neurol
|
2010
|
1.39
|
|
33
|
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.
|
Acta Neuropathol
|
2010
|
1.38
|
|
34
|
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
|
PLoS One
|
2011
|
1.32
|
|
35
|
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.
|
Arch Neurol
|
2012
|
1.32
|
|
36
|
Neurodegeneration across stages of cognitive decline in Parkinson disease.
|
Arch Neurol
|
2011
|
1.26
|
|
37
|
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment.
|
Ann Neurol
|
2005
|
1.23
|
|
38
|
Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.
|
J Nucl Med
|
2006
|
1.22
|
|
39
|
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease.
|
Brain
|
2011
|
1.22
|
|
40
|
A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging.
|
Stat Med
|
2004
|
1.18
|
|
41
|
T1rho MRI of Alzheimer's disease.
|
Neuroimage
|
2008
|
1.13
|
|
42
|
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
|
J Neurol Neurosurg Psychiatry
|
2012
|
1.12
|
|
43
|
Visual perceptual functions predict instrumental activities of daily living in patients with dementia.
|
Neuropsychiatry Neuropsychol Behav Neurol
|
2002
|
1.10
|
|
44
|
Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale.
|
Alzheimer Dis Assoc Disord
|
2009
|
1.09
|
|
45
|
Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
|
Alzheimer Dis Assoc Disord
|
2012
|
1.08
|
|
46
|
Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center.
|
Am J Geriatr Psychiatry
|
2011
|
1.06
|
|
47
|
Incorporating clonal growth form clarifies the role of plant height in response to nitrogen addition.
|
Oecologia
|
2012
|
1.05
|
|
48
|
Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease.
|
Alzheimers Dement
|
2009
|
1.05
|
|
49
|
Rank clocks and plant community dynamics.
|
Ecology
|
2008
|
1.03
|
|
50
|
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
|
Alzheimer Dis Assoc Disord
|
2006
|
1.01
|
|
51
|
Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.
|
J Alzheimers Dis
|
2012
|
1.01
|
|
52
|
Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study.
|
Acta Neuropathol
|
2003
|
1.00
|
|
53
|
Informed consent for Alzheimer's disease clinical trials: a survey of clinical investigators.
|
IRB
|
2003
|
0.98
|
|
54
|
Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
|
Arch Neurol
|
2010
|
0.97
|
|
55
|
T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia.
|
J Neurol
|
2010
|
0.97
|
|
56
|
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
|
J Neuropathol Exp Neurol
|
2014
|
0.94
|
|
57
|
The C. elegans touch response facilitates escape from predacious fungi.
|
Curr Biol
|
2011
|
0.93
|
|
58
|
Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome.
|
Mol Cell Proteomics
|
2011
|
0.92
|
|
59
|
Memory encoding and retrieval in frontotemporal dementia and Alzheimer's disease.
|
Neuropsychology
|
2002
|
0.91
|
|
60
|
Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
|
Alzheimer Dis Assoc Disord
|
2009
|
0.89
|
|
61
|
Early marker for Alzheimer's disease: hippocampus T1rho (T(1rho)) estimation.
|
J Magn Reson Imaging
|
2009
|
0.88
|
|
62
|
Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study.
|
Alzheimers Dement
|
2012
|
0.88
|
|
63
|
Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials.
|
Alzheimer Dis Assoc Disord
|
2006
|
0.88
|
|
64
|
Emotion-discrimination deficits in mild Alzheimer disease.
|
Am J Geriatr Psychiatry
|
2005
|
0.88
|
|
65
|
Biofuels: network analysis of the literature reveals key environmental and economic unknowns.
|
Environ Sci Technol
|
2012
|
0.86
|
|
66
|
Relationship between Alzheimer's disease severity and patient participation in decisions about their medical care.
|
J Geriatr Psychiatry Neurol
|
2002
|
0.85
|
|
67
|
Validation of consensus panel diagnosis in dementia.
|
Arch Neurol
|
2010
|
0.85
|
|
68
|
Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma.
|
Carcinogenesis
|
2003
|
0.84
|
|
69
|
Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus.
|
Fluids Barriers CNS
|
2012
|
0.84
|
|
70
|
T(1ρ) MRI in Alzheimer's disease: detection of pathological changes in medial temporal lobe.
|
J Neuroimaging
|
2011
|
0.84
|
|
71
|
Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2010
|
0.84
|
|
72
|
Comparative multiresolution wavelet analysis of ERP spectral bands using an ensemble of classifiers approach for early diagnosis of Alzheimer's disease.
|
Comput Biol Med
|
2006
|
0.83
|
|
73
|
Disturbed visual processing contributes to impaired reading in Alzheimer's disease.
|
Neuropsychologia
|
2002
|
0.83
|
|
74
|
Frontotemporal lobar degeneration with motor neuron disease: a clinical and pathological spectrum.
|
Arch Neurol
|
2006
|
0.82
|
|
75
|
Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology.
|
Alzheimers Dement
|
2012
|
0.82
|
|
76
|
F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patients.
|
Cogn Behav Neurol
|
2008
|
0.81
|
|
77
|
Why would caregivers not want to treat their relative's Alzheimer's disease?
|
J Am Geriatr Soc
|
2003
|
0.80
|
|
78
|
Visual processing impairments and decrements in regional brain activity in Alzheimer's disease.
|
J Clin Exp Neuropsychol
|
2004
|
0.80
|
|
79
|
ERP based decision fusion for AD diagnosis across cohorts.
|
Conf Proc IEEE Eng Med Biol Soc
|
2009
|
0.79
|
|
80
|
Memory distortion in Alzheimer's disease: deficient monitoring of short- and long-term memory.
|
Neuropsychology
|
2012
|
0.78
|
|
81
|
Failure of biomarkers in clinical trials of Alzheimer's disease: blaming the messenger?
|
J Alzheimers Dis
|
2009
|
0.75
|
|
82
|
The Dementia Severity Rating Scale predicts clinical dementia rating sum of boxes scores.
|
Alzheimer Dis Assoc Disord
|
2015
|
0.75
|
|
83
|
5-Iodobenzofurazan 1-oxide: polymorphs, pseudosymmetry and disorder.
|
Acta Crystallogr C
|
2008
|
0.75
|
|
84
|
Cognitive function assessment in individuals at risk for Alzheimer's disease.
|
J Am Acad Nurse Pract
|
2003
|
0.75
|
|
85
|
Stacked generalization for early diagnosis of Alzheimer's disease.
|
Conf Proc IEEE Eng Med Biol Soc
|
2006
|
0.75
|
|
86
|
Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments.
|
Neurobiol Aging
|
2002
|
0.75
|
|
87
|
Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease.
|
Neurochem Res
|
2011
|
0.75
|
|
88
|
Four polymorphs (polytypes) of 5,6-dimethylbenzofurazan 1-oxide.
|
Acta Crystallogr B
|
2012
|
0.75
|
|
89
|
EEG and MRI data fusion for early diagnosis of Alzheimer's disease.
|
Conf Proc IEEE Eng Med Biol Soc
|
2008
|
0.75
|